feedback

Activity Details

Free CME/CNE
1.0 AMA PRA Category 1 Credit(s)
1.0 ANCC Contact Hour(s)
1.0 AANP Contact Hour(s)
Released: September 16, 2020
Expires: September 15, 2021
1 hour to complete

Accredited By

Target Audience

Gastroenterologists, physician assistants, nurse practitioners, nurses and other healthcare providers who manage patients with inflammatory bowel disease.

Learning Objectives

At the end of the activity, participants will be better able to:

  • Summarize the relative risk and signs of SARS-CoV-2 infection among patients with ulcerative colitis (UC)
  • Modify management and education of UC patients not infected with SARS-CoV-2 in order to reduce the risk of such infection
  • Safely modify UC treatments in patients testing positive for SARS-CoV-2 but asymptomatic
  • Safely modify UC treatments in patients with symptomatic COVID-19, including those with active UC inflammation

Activity Description

The COVID-19 pandemic is an unprecedented challenge for all healthcare systems worldwide. Gastroenterologists and clinicians who actively manage patients with inflammatory bowel disease (IBD), including ulcerative colitis (UC), need to ensure they are taking steps to minimize the risk of infection for their patients.

Russell D. Cohen, MD, shares his expert perspective as an author of the recently published AGA Clinical Practice Update on Management of Inflammatory Bowel Disease During the COVID-19 Pandemic. Dr. Cohen highlights emerging evidence and the potential risk of IBD patients for COVID-19, as well as recommendations for the treatment and management of patients with IBD during the coronavirus pandemic. In addition, he reviews the publicly accessible SECURE-IBD international registry and its impact tracking COVID-19 in patients with IBD. Dr. Cohen further discusses how to identify, appropriately manage, and monitor patients with UC who test positive for COVID-19, through the use of an algorithm to guide complex clinical decisions for those who are symptomatic with or without suspicion of active UC inflammation.

Statement of Educational Need

  • Clinicians need to improve their knowledge about the risks and signs of SARS-CoV-2 infection among patients with UC
  • Clinicians need to improve their competency managing and educating UC patients to help reduce their risk of exposure to and infection of SARS-CoV-2
  • Clinicians need to improve their competency modifying UC treatments in patients testing positive for SARS-CoV-2, but who are asymptomatic, to reduce risk of developing COVID-19
  • Clinicians need to improve their competency modifying UC treatments in patients with symptomatic COVID-19, taking into account the severity of their symptoms
  • Clinicians need to improve their competency modifying UC treatments in patients with symptomatic COVID-19 with active inflammation, taking into account the severity of their COVID-19 and UC symptoms

Agenda

  • Risks, signs of SARS-CoV-2 in IBD population; clinical outcomes with COVID-19
  • Management of UC patients not infected with SARS-CoV-2
  • Medication management of UC patients testing positive for SARS-CoV-2 but who are asymptomatic
  • Medication management of UC patients with symptomatic COVID-19
  • Medication management of UC patients with symptomatic COVID-19 with active inflammation

Faculty

Russell D. Cohen, MD
Professor of Medicine, Pritzker School of Medicine
Director, Inflammatory Bowel Disease Center
Co-Director, Advanced IBD Fellowship Program
The University of Chicago Medicine
Chicago, Illinois

Conflict of Interest Policy/Disclosure Statement

It is the policy of the Annenberg Center for Health Sciences to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All faculty and planners participating in sponsored programs are expected to identify and reference off-label product use and disclose any relationship with those supporting the activity or any others with products or services available within the scope of the topic being discussed in the educational presentation.

The Annenberg Center for Health Sciences assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE/CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CE/CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

In accordance with the Accreditation Council for Continuing Medical Education Standards, parallel documents from other accrediting bodies, and Annenberg Center for Health Sciences policy, the following disclosures have been made:

Russell D. Cohen, MD
Speaker bureau
AbbVie – clinical area: Inflammatory Bowel Disease
Takeda – clinical area: Inflammatory Bowel Disease

Consultant
AbbVie – clinical area: Inflammatory Bowel Disease
Celgene – clinical area: Inflammatory Bowel Disease
Entera Health – clinical area: Inflammatory Bowel Disease
Hospira – clinical area: Inflammatory Bowel Disease
Janssen – clinical area: Inflammatory Bowel Disease
Pfizer Inc. – clinical area: Inflammatory Bowel Disease
Sandoz – clinical area: Inflammatory Bowel Disease
Takeda – clinical area: Inflammatory Bowel Disease
UCB – clinical area: Inflammatory Bowel Disease

Research Support
AstraZeneca – clinical area: Inflammatory Bowel Disease
Celgene – clinical area: Inflammatory Bowel Disease
Gilead Sciences – clinical area: Inflammatory Bowel Disease
MedImmune – clinical area: Inflammatory Bowel Disease
Mesoblast – clinical area: Inflammatory Bowel Disease
Osiris Therapeutics – clinical area: Inflammatory Bowel Disease
Pfizer Inc. – clinical area: Inflammatory Bowel Disease
Receptos – clinical area: Inflammatory Bowel Disease
RedHill Biopharma – clinical area: Inflammatory Bowel Disease
Sanofi US – clinical area: Inflammatory Bowel Disease
UCB – clinical area: Inflammatory Bowel Disease

Dr. Cohen’s spouse is on the Board of Directors for Aerpio Therapeutics, Novus Therapeutics, Vital Therapies, Inc., and NantKwest.

The faculty for this activity have disclosed that there will be no discussion about the use of products for non-FDA approved applications.

Additional content planners
Victoria Anderson (Medical writer)

Individual stockholder
Abbott – clinical area: N/A
AbbVie – clinical area: N/A

The following have no significant relationship to disclose:
Heather M. Jimenez, FNP-C (Nurse Planner)

Annenberg Center for Health Sciences
All staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of the Annenberg Center and/or its agents. As in all educational activities, we encourage practitioners to use their own judgment in treating and addressing the needs of each individual patient, taking into account that patient’s unique clinical situation. The Annenberg Center disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.

Accreditation Statement

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Annenberg Center for Health Sciences at Eisenhower is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 040207.
This program is accredited for 1.0 contact hour. Program ID #5864-EM

Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

A maximum of 1.0 contact hours may be earned for successful completion of this activity.

Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1.0 contact hours. To receive credit for education contact hours outside of the state of California, please check with your state board of registered nursing for reciprocity.

Statement of Commercial Support

This activity is supported by an independent educational grant from Pfizer Inc.

Contact Information for Questions About the Activity

For help or questions about this activity, please contact Continuing Education:
ce@annenberg.net
Annenberg Center for Health Sciences
39000 Bob Hope Drive
Dinah Shore Building
Rancho Mirage, CA 92270
Phone 760-773-4500
Fax 760-773-4513
8 AM – 5 PM, Pacific Time, Monday – Friday

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Start Activity

Select your specialty

You must select a specialty

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.